Etienne Harry, Kalt Fabian, Park Samina, Opitz Isabelle
Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
J Surg Oncol. 2023 Feb;127(2):296-307. doi: 10.1002/jso.27183.
Extended lung resections for T3-T4 non-small-cell lung cancer remain challenging. Multimodal management is mandatory in multidisciplinary tumor boards, and here the determination of resectability is key. Long-term oncologic efficacy depends mostly on complete resection (R0) and the extent of N2 disease. The development of novel innovative treatments (targeted therapy and immune checkpoint inhibitors) sets interesting perspectives to reinforce current therapeutic options in the induction and adjuvant setting.
对T3 - T4期非小细胞肺癌进行扩大肺切除术仍然具有挑战性。在多学科肿瘤委员会中，多模式管理是必不可少的，而确定可切除性是关键。长期肿瘤学疗效主要取决于完全切除（R0）和N2期疾病的范围。新型创新疗法（靶向治疗和免疫检查点抑制剂）的发展为加强诱导和辅助治疗中的现有治疗选择提供了有趣的前景。
